-
Loading metrics
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective
- Freekje van Asten,
- Charlotte T. J. Michels,
- Carel B. Hoyng,
- Gert Jan van der Wilt,
- B. Jeroen Klevering,
- Maroeska M. Rovers,
- Janneke P. C. Grutters
x
- Published: May 17, 2018
- https://doi.org/10.1371/journal.pone.0197670